Estrogen Hormone Products
Study Details
Study Description
Brief Summary
The purpose is to determine if the two estradiol products can deliver similar amounts of estradiol after single and multiple dosing.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Early Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: EstroGel® 0.06% EstroGel® 0.06% (1.25 g of gel/dose) |
Drug: Estradiol
estradiol topical products
|
| Active Comparator: Compounded estradiol product Compounded estradiol product (equivalent to EstroGel®/dose) |
Drug: Estradiol
estradiol topical products
|
Outcome Measures
Primary Outcome Measures
- PK [-1 through 12 hours for four consecutive days]
serum concentrations
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Postmenopausal women, who are of any ethnic background, between the age of 45 to 65 years old
-
Provide written informed consent before initiation of any of the study procedures
-
Able to adhere to the study restrictions and study schedule
-
Volunteer has mid thighs of at least 42 cm (16.5 in) in circumference to accommodate the products to be tested at an area of 400 cm2 per thigh
-
Volunteer has legs that measure ≥46 cm (18.1 in) in length from the iliac crest to the top of the patella or large enough to accommodate the products to be tested at an area of 400 cm2 per thigh with the subject being comfortable with the template placement
-
Volunteer deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination, and medication history
-
Negative urine drug screening test (cannabinoids, amphetamines, barbiturates, benzodiazepine, cocaine, methadone, opiates, PCP)
-
Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT), and aspartate aminotransferase (AST)
-
Have normal screening laboratories for urine protein and urine glucose
-
Naturally postmenopausal (absence of periods for ≥ 1 year or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy (menopause induced by removal of ovaries)
-
Agree not to participate in another clinical trial/study or to participate in an investigational drug study for at least one month after the last procedure day
-
Agrees not to donate blood to a blood bank throughout participation in the study and for at least three months after last procedure day
-
Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)
-
Have normal vital signs:
-
Temperature 35-37.9°C (95-100.3°F)
-
Systolic blood pressure 90-140 mmHg
-
Diastolic blood pressure 60-90 mmHg
-
Heart rate 55-100 beats per minute
-
Respiration rate 12-20 breaths per minute
Exclusion Criteria:
-
Smokers/tobacco users (current use or use over the previous 2 months of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches, or electronic cigarettes)
-
Participation in any ongoing clinical drug trial/study
-
Hereditary skin disorders or any skin inflammatory conditions as reported by the volunteer or evident to the MAI
-
History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma) except basal cell carcinomas that were superficial and did not involve the investigative sites
-
History as either reported by the volunteer or evident to the investigator of infectious disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic dermatitis)
-
Use of chronic prescription medications during the period 0 to 30 days; or over-the-counter medications (e.g. antihistamines, topical corticosteroids) and short term (<30 days) prescription medications during the period 0-3 days before a procedure day vitamin and herbal supplements not included)
-
Active positive Hepatitis B, C and/or HIV serologies
-
Positive urine drug screening test
-
Use of estrogen-containing implants, topical, or oral products
-
Donation or loss of greater than one pint of blood within 60 days of entry to the study
-
Any prior allergies to estradiol and its products or other ingredients in the applied gels
-
Received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within one month before enrollment in this study or expects to receive an experimental agent during the study
-
Any condition that would, in the opinion of the Medically Accountable Investigator (MAI), place the volunteer at an unacceptable risk of injury or render the volunteer unable to meet the requirements of the protocol
-
History of diabetes
-
Breast cancer or history of breast cancer
-
Undiagnosed abnormal genital bleeding
-
Estrogen-dependent neoplasia (tumor)
-
Active arterial thromboembolic disease (example, stroke or heart attack), or a history of these conditions
-
Active DVT (blood clots in deep vein such as lower leg, thigh, pelvis or can occur in arm), PE (blood clot in blood vessel; often leg), or history of these conditions
-
Hepatic (liver) impairment or disease
-
Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (tendency to form blood clots)
-
At application site, volunteer has an obvious difference in skin color between thighs, presence of a skin condition, excessive hair, sunburn, raised moles and scars, open sores, scar tissue, tattoo, or coloration that would interfere with placement of products, skin assessment, or reactions to estradiol
-
BMI ≥30 kg/m2
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Maryland, Baltimore
Investigators
- Principal Investigator: Audra Stinchcomb, PhD, University of Maryland, Baltimore
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HP-00100540